Thursday, October 11, 2012
The trial will be held in 2013 at Washington University School of Medicine.
Leading scientists have selected the first drugs to be evaluated in a worldwide clinical study to determine whether they can prevent Alzheimer’s disease. The pioneering trial, expected to start by early 2013, initially will test three promising drugs, each designed to target Alzheimer’s in different ways. In people with inherited mutations that cause early-onset Alzheimer’s, the study will seek to identify whether the drugs can improve Alzheimer’s disease biomarkers and effectively prevent the loss of cognitive function. “This trial is the result of a groundbreaking collaboration between academic institutions, pharmaceutical companies and patient advocacy groups, with key support from regulatory groups,” said principal investigator Randall…
Friday, September 7, 2012
According to new study from the Washington University School of Medicine.
Sleep disruptions may be among the earliest indicators of Alzheimer’s disease, scientists at Washington University School of Medicine in St. Louis report Sept. 5 in Science Translational Medicine. Working in a mouse model, the researchers found that when the first signs of Alzheimer’s plaques appear in the brain, the normal sleep-wake cycle is significantly disrupted. “If sleep abnormalities begin this early in the course of human Alzheimer’s disease, those changes could provide us with an easily detectable sign of pathology,” said senior author David M. Holtzman, MD, the Andrew B. and Gretchen P. Jones Professor and head of Washington University’s Department of Neurology. “As we start to treat Alzheimer’s patients before the onset of …
Monday, April 23, 2012
According to study from Washington University.
- NEWS
-
Monday, April 23, 2012
Scientists studying the way Alzheimer’s takes root in the brain have identified important new similarities between a mouse model and human Alzheimer’s. Researchers at Washington University School of Medicine in St. Louis have shown that brain plaques in mice are associated with disruption of the ability of brain regions to network with each other. This decline parallels earlier results from human studies, suggesting that what scientists learn about Alzheimer’s effects on brain networks in the mice will likely be transferable to human disease research. The study, published in the Journal of Neuroscience, is among the first to precisely quantify the effects of Alzheimer’s disease plaques on brain networks in an animal model. Until now, …
Tuesday, March 13, 2012
According to Washington University School of Medicine study.
- NEWS
-
Tuesday, March 13, 2012
A new marker of Alzheimer’s disease can predict how rapidly a patient’s memory and other mental abilities will decline after the disorder is diagnosed, researchers at Washington University School of Medicine in St. Louis have found. In 60 patients with early Alzheimer’s disease, higher levels of the marker, visinin-like protein 1 (VILIP-1), in the spinal fluid were linked to a more rapid mental decline in the years that followed. Scientists need to confirm the results in larger studies, but the new data suggest that VILIP-1 potentially may be a better predictor of Alzheimer’s progression than other markers. “VILIP-1 appears to be a strong indicator of ongoing injury to brain cells as a result of Alzheimer’s disease,” says lead author …
Janet Daley
11:29 am on Tuesday, March 13, 2012
All Alzheimer's and heart disease can be reversed in many people by using a specialized diabetes diet. This was proven in Scandinavia News. You may not have diabetes but Alzheimer's is related to blood sugar. Alzheimer's and diabetes has risen at the same exact level over the last 30 years. A specialized diabetes diet in Denmark was shown to improve memory in Dementia and Alzheimer's sufferers. … more ›